Table 1.

Topics and involved content of the top 100 articles.

	Theme	Publications	Involved content
Immunotherapy	Immune checkpoint inhibitors	21	Pd-1/pd-l1inhibitors*13 (including Dostarlimab, Pembrolizumab, Nivolumab, Avelumab, Durvalumab, Tremelimumab)
	Combination therapy	10	Immunotherapy combined with targeted therapy (Pembrolizumab + Lenvatinib)*6, immunotherapy combined with radiotherapy*2, dual immunotherapy*2
	Immune cell therapy	5	Dendritic cell*3, CAR-T*2
Immune microenvironment mechanism	Immune checkpoint	26	PD-1, TIM-3, IDO, CD47, Inducible Hsp70, B7-H4, Foxp3, LAG-3, CTA
	Gene and molecular typing	23	Mutation, Hypermutation, Mismatch repair, Microsatellite instability

The value after the asterisk (*) is the number of involved content by the topic.

CAR-T = chimeric antigen receptor-T, PD-1/PD-L1 = programmed death-1/programmed death ligand-1.